Clinical trials: open to volunteers, in Norway
Pyoderma Gangrenosum
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to closure of PG ulcers.
- Trial name
- NCT06624670
- Testing
- Spesolimab, Prednisone, Prednisolone
- Where
- 104 sites in United States, Argentina and 19 more
- Volunteers
- 90 people
- Sponsor
- LEO Pharma
Gout Initiating Urate-loweringUrate-lowering Therapy
The Remote Monitoring of Gout Study
The goal of this clinical trial is to: compare a new digital self-management treatment strategy to usual care, for patients with gout receiving urate lowering therapy in specialist healthcare.
- Trial name
- ReMonit Gout (NCT06822933)
- Testing
- Urika, Nurse-led follow-up with telephone consultations.
- Where
- Norway
- Volunteers
- 168 people
- Sponsor
- Diakonhjemmet Hospital
Kidney Disease
A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy
Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation).
- Trial name
- NCT06963827
- Testing
- Mezagitamab
- Where
- 181 sites in United States, Argentina and 24 more
- Volunteers
- 347 people
- Sponsor
- Takeda
Substance Use Disorder (SUD)
Fighting Addictions, Improving Lives: COmprehensive Drug Rehabilitation With Music
FALCO is a parallel pragmatic randomized control trial addressing long-term effects of music therapy (MT) on substance use disorder (SUD). 600 participants will be recruited from multiple European countries (see Locations).
- Trial name
- FALCO (NCT07028983)
- Testing
- Active Music Group (AMG), Music Listening Group (MLG), Treatment as Usual (TAU)
- Where
- 11 sites in Austria, Israel and 6 more
- Volunteers
- 600 people
- Sponsor
- NORCE Norwegian Research Centre AS
Metastatic Non-small Cell Lung Cancer With MTAP Deletion
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab…
- Trial name
- MountainTAP-29 (NCT07063745)
- Testing
- BMS-986504, Pembrolizumab, Cisplatin
- Where
- 321 sites in United States, Argentina and 32 more
- Volunteers
- 590 people
- Sponsor
- Bristol-Myers Squibb
Chronic Obstructive Pulmonary Disease
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
This is a parallel, Phase 2b/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig compared with placebo in adult participants (aged 40 to 80 years, inclusive)…
- Trial name
- THESEUS (NCT07190222)
- Testing
- Lunsekimig
- Where
- 314 sites in United States, Argentina and 24 more
- Volunteers
- 942 people
- Sponsor
- Sanofi
Non-Small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
- Trial name
- NCT07361510
- Testing
- Pumitamig, Pembrolizumab
- Where
- 283 sites in United States, Argentina and 34 more
- Volunteers
- 750 people
- Sponsor
- Bristol-Myers Squibb
Primary Sclerosing Cholangitis
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
The purpose of this study is to find out how well and safely elafibranor works compared to placebo in adult participants with Primary sclerosing cholangitis (PSC).
- Trial name
- ELASCOPE (NCT07387549)
- Testing
- Elafibranor
- Where
- 231 sites in United States, Argentina and 23 more
- Volunteers
- 350 people
- Sponsor
- Ipsen
Gastrointestinal Stromal Neoplasms
A Study to Investigate Velzatinib Compared With Imatinib in Adult Participants With Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (StrateGIST Frontline)
Gastrointestinal Stromal Tumour (GIST) is a soft tissue tumour that develops in the digestive system, most often in the stomach or small intestine.
- Trial name
- NCT07585266
- Testing
- Velzatinib, Imatinib
- Where
- 93 sites in United States, Argentina and 18 more
- Volunteers
- 800 people
- Sponsor
- GlaxoSmithKline
Gut Microbiota Diversity and Composition, Gut Microbiota Modulation
Effects of Barley and Kefir on Gut Microbiota in Physically Active Adults
The purpose of this randomized controlled clinical trial is to investigate whether a four-week dietary intervention consisting of a daily meal with barley and kefir can influence gut microbiota diversity and composition in…
- Conditions
- Gut Microbiota Diversity and Composition, Gut Microbiota Modulation, Probiotic, Prebiotic
- Trial name
- GUTS (NCT07864779)
- Testing
- Barley, Kefir
- Where
- Norway
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Western Norway University of Applied Sciences
Bladder Cancer, Urinary Bladder Neoplasms
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Researchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder and has not spread to the bladder muscle or outside of the…
- Trial name
- NCT07222488
- Testing
- MK-3120
- Where
- 17 sites in United States, Austria and 10 more
- Volunteers
- 45 people
- Sponsor
- Merck Sharp & Dohme LLC
Alcoholic Liver Disease (ALD), Alcohol Use Disorder
Elastography-based Brief Alcohol Intervention in Hospitalized Individuals
Harmful alcohol use is a common cause of hospital admissions and the leading cause of liver cirrhosis. Timely detection of liver disease is crucial to prevent liver disease progression and reduce alcohol-related harms.
- Trial name
- PREDILECTION (NCT07637539)
- Testing
- Elastography-based brief alcohol intervention
- Where
- 8 sites in Norway
- Volunteers
- 500 people
- Sponsor
- Oslo University Hospital
Soft Tissue Sarcoma
Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma
Nearly half of patients with high-grade, localized soft tissue sarcoma (STS) of extremities and trunk wall develop disease recurrence after local therapy.
- Trial name
- NCT04776525
- Testing
- Ifosfamide, Doxorubicin
- Where
- 2 sites in Norway
- Volunteers
- 49 people
- Sponsor
- Oslo University Hospital
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
This is a study to evaluate the efficacy and safety of belzutifan monotherapy in participants with advanced pheochromocytoma/paraganglioma (PPGL), pancreatic neuroendocrine tumor (pNET), von Hippel-Lindau (VHL) disease-associated…
- Conditions
- Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor, Von Hippel-Lindau Disease, Advanced Gastrointestinal Stromal Tumor
- Trial name
- NCT04924075
- Testing
- Belzutifan
- Where
- 84 sites in United States, Australia and 20 more
- Volunteers
- 355 people
- Sponsor
- Merck Sharp & Dohme LLC
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
The BIOMEDE 2.0 study is the second stage of the BIOMEDE multi-arm, multistage rolling programme (adaptive platform protocol). It is a multicenter, randomized, open-label, controlled phase-3 trial evaluating efficacy of ONC201 in…
- Conditions
- Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3K27-altered
- Trial name
- BIOMEDE 2 (NCT05476939)
- Testing
- Everolimus, ONC201, Radiotherapy
- Where
- 56 sites in Belgium, Denmark and 6 more
- Volunteers
- 433 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Gastro Esophageal Reflux Disease
Endoscopic Treatment of Gastroesophageal Reflux Disease
Gastroesophageal reflux disease (GERD) occurs when stomach acid repeatedly flows back into the tube connecting your mouth and stomach (esophagus). This backwash (acid reflux) can irritate the inner lining of the esophagus.
- Trial name
- NCT05678491
- Testing
- Endoscopic mucosal band ligation
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- St. Olavs Hospital
Agitation in Dementia, Including Alzheimer's Disease
Virtual Darkness Theraphy for Agitation in Dementia
Behavioral and psychological symptoms of dementia (BPSD) such as anxiety, depression, psychosis and agitation, are prevalent, often treatment resistant, resource demanding and significantly deteriorates cognition, independency…
- Trial name
- DARKDEM (NCT06451952)
- Testing
- Virtual darkness
- Where
- Norway
- Volunteers
- 72 people
- Sponsor
- University of Bergen
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
The purpose of this study is to obtain safety, efficacy, and pharmacodynamic data on the use of vutrisiran in patients with ATTR amyloidosis with cardiomyopathy who continued on extended use of vutrisiran, or switched from…
- Trial name
- NCT06679946
- Testing
- Vutrisiran
- Where
- 87 sites in United States, Argentina and 15 more
- Volunteers
- 700 people
- Sponsor
- Alnylam Pharmaceuticals
Crohn's Disease
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
This is a multinational, multicenter, randomized, double-blind, placebo-controlled, Phase 3 induction study, comprised of 3 sub-studies, to evaluate the efficacy and safety of duvakitug in participants with moderately to severely…
- Trial name
- STARSCAPE-1 (NCT07184931)
- Testing
- Duvakitug
- Where
- 461 sites in United States, Argentina and 34 more
- Volunteers
- 980 people
- Sponsor
- Sanofi
Prostate Cancer
Prostate Risk Or Radiology Assessment Non-inferiority Design, Upfront MRI or Risk Calculator in Men With Suspected Prostate Cancer
Thousands of men take a PSA test to investigate whether they have prostate cancer every year. For the vast majority, the test is normal and further investigations are not necessary.
- Trial name
- PRORAND (NCT07422597)
- Testing
- European Study of screening for prostate cancer risk calculator
- Where
- 3 sites in Norway
- Volunteers
- 1,016 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology